Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.
Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C, Narakorn P, Surichan S, Prangpratanporn S, Puksuriwong S, Lamola S, Mercer LD, Raghunandan R, Sun W, Liu Y, Carreño JM, Scharf R, Phumratanaprapin W, Amanat F, Gagnon L, Hsieh CL, Kaweepornpoj R, Khan S, Lal M, McCroskery S, McLellan J, Mena I, Meseck M, Phonrat B, Sabmee Y, Singchareon R, Slamanig S, Suthepakul N, Tcheou J, Thantamnu N, Theerasurakarn S, Tran S, Vilasmongkolchai T, White JA, Garcia-Sastre A, Palese P, Krammer F, Poopipatpol K, Wirachwong P, Hjorth R, Innis BL. Pitisuttithum P, et al. Among authors: mclellan j. medRxiv [Preprint]. 2021 Sep 22:2021.09.17.21263758. doi: 10.1101/2021.09.17.21263758. medRxiv. 2021. Update in: EClinicalMedicine. 2022 Mar 08;45:101323. doi: 10.1016/j.eclinm.2022.101323 PMID: 34580673 Free PMC article. Updated. Preprint.
Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19.
Kaplonek P, Wang C, Bartsch Y, Fischinger S, Gorman MJ, Bowman K, Kang J, Dayal D, Martin P, Nowak R, Hsieh CL, Feldman J, Julg B, Nilles EJ, Musk ER, Menon AS, Fischer ES, McLellan JS, Schmidt A, Goldberg MB, Filbin M, Hacohen N, Lauffenburger DA, Alter G. Kaplonek P, et al. Among authors: mclellan js. bioRxiv [Preprint]. 2021 May 12:2021.05.11.443609. doi: 10.1101/2021.05.11.443609. bioRxiv. 2021. Update in: Sci Immunol. 2021 Oct 15;6(64):eabj2901. doi: 10.1126/sciimmunol.abj2901 PMID: 34013263 Free PMC article. Updated. Preprint.
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
Walls AC, Miranda MC, Pham MN, Schäfer A, Greaney A, Arunachalam PS, Navarro MJ, Tortorici MA, Rogers K, O'Connor MA, Shireff L, Ferrell DE, Brunette N, Kepl E, Bowen J, Zepeda SK, Starr T, Hsieh CL, Fiala B, Wrenn S, Pettie D, Sydeman C, Johnson M, Blackstone A, Ravichandran R, Ogohara C, Carter L, Tilles SW, Rappuoli R, O'Hagan DT, Van Der Most R, Van Voorhis WC, McLellan JS, Kleanthous H, Sheahan TP, Fuller DH, Villinger F, Bloom J, Pulendran B, Baric R, King N, Veesler D. Walls AC, et al. Among authors: mclellan js. bioRxiv [Preprint]. 2021 Mar 16:2021.03.15.435528. doi: 10.1101/2021.03.15.435528. bioRxiv. 2021. Update in: Cell. 2021 Oct 14;184(21):5432-5447.e16. doi: 10.1016/j.cell.2021.09.015 PMID: 33758839 Free PMC article. Updated. Preprint.
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination.
Voss WN, Mallory MA, Byrne PO, Marchioni JM, Knudson SA, Powers JM, Leist SR, Dadonaite B, Townsend DR, Kain J, Huang Y, Satterwhite E, Castillo IN, Mattocks M, Paresi C, Munt JE, Scobey T, Seeger A, Premkumar L, Bloom JD, Georgiou G, McLellan JS, Baric RS, Lavinder JJ, Ippolito GC. Voss WN, et al. Among authors: mclellan js. bioRxiv [Preprint]. 2024 Jan 23:2024.01.22.576742. doi: 10.1101/2024.01.22.576742. bioRxiv. 2024. Update in: Cell Rep Med. 2024 Aug 20;5(8):101668. doi: 10.1016/j.xcrm.2024.101668 PMID: 38545622 Free PMC article. Updated. Preprint.
Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking.
Shiakolas AR, Johnson N, Kramer KJ, Suryadevara N, Wrapp D, Periasamy S, Pilewski KA, Raju N, Nargi R, Sutton RE, Walker L, Setliff I, Crowe JE, Bukreyev A, Carnahan RH, McLellan JS, Georgiev IS. Shiakolas AR, et al. Among authors: mclellan js. bioRxiv [Preprint]. 2021 Jun 30:2021.06.02.446813. doi: 10.1101/2021.06.02.446813. bioRxiv. 2021. Update in: Nat Biotechnol. 2022 Aug;40(8):1270-1275. doi: 10.1038/s41587-022-01232-2 PMID: 34100018 Free PMC article. Updated. Preprint.
Distinct pathway for evolution of enhanced receptor binding and cell entry in SARS-like bat coronaviruses.
Tse AL, Acreman CM, Ricardo-Lax I, Berrigan J, Lasso G, Balogun T, Kearns FL, Casalino L, McClain GL, Chandran AM, Lemeunier C, Amaro RE, Rice CM, Jangra RK, McLellan JS, Chandran K, Miller EH. Tse AL, et al. Among authors: mclellan js. bioRxiv [Preprint]. 2024 Jul 13:2024.06.24.600393. doi: 10.1101/2024.06.24.600393. bioRxiv. 2024. Update in: PLoS Pathog. 2024 Nov 15;20(11):e1012704. doi: 10.1371/journal.ppat.1012704 PMID: 38979151 Free PMC article. Updated. Preprint.
372 results